Research Studies

Solid Tumor Program Research Studies

Find research studies available to children cared for by the Solid Tumor Program team.
Existing patients or family members
New patients, referrals and second opinions

Search Research Studies

Clinical trial
Children (17)
Adults (16)
MRI/Imaging Studies (2)

Clinical Trial Phases
Phase I (9)
Phase II (13)
N/A (1)

Recruitment Status
Recruiting (15)
Non-recruiting (2)

Related Specialties and Programs
Cancer Center (17)
Solid Tumor Program (17)
Cancer Immunotherapy Program (1)
Leukemia and Lymphoma Program (1)

Specialty
Oncology (17)

Afamitresgene Autoleucel in Pediatric Subjects with MAGE-A4 Positive Tumors
This study involves an investigational cellular therapy called Afamitresgene Autoleucel. The overall goal of this study is to find out how safe and effective this cellular therapy is in treating people that have been diagnosed with synovial sarcoma, malignant peripheral nerve sheath tumors (MPNST), neuroblastoma or osteosarcoma that has grown or returned after being treated.   

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

BA3011 for advanced solid tumors

This study involves taking a study drug called BA3011. Theoverall goal of this study is to see if BA3011 is a possible treatment forpatients with sarcoma.

Phase: Phase I, Phase II

Actively recruiting: No

Category: Adults, Children

Cabo/Ifos in Ewing Sarcoma and Osteosarcoma (CaIRS trial)
This study enrolls patients between 5 and 40 years of age with a diagnosis of Ewing sarcoma (including Ewing-like sarcoma) or osteosarcoma that has progressed on or relapsed after upfront initial therapy. The purpose of this study is to find the best dose of a drug called cabozantinib (“the study drug”) to give to patients in combination with a routine chemotherapy drug called ifosfamide. 

Phase: Phase I

Actively recruiting: Yes

Category: Adults, Children

GD2CART for Osteosarcoma or Neuroblastoma
This study enrolls patients that have been diagnosed with osteosarcoma or neuroblastoma that has come back (relapsed) or has not responded to standard treatments (refractory). This study involves an investigational cellular therapy called GD2CART. The study will be testing different doses of the study drug to find the safest dose.

Phase: Phase I

Actively recruiting: Yes

Category: Adults, Children

Larotrectinib RAI Thyroid (LANTERN)
This study enrolls patients with newly diagnosed differentiated thyroid cancer (papillary thyroid cancer or follicular thyroid cancer) that has spread to the lungs and has a genetic mutation called and NTRK fusion. The study involves taking a study drug called larotrectinib for approximately 6 months prior to receiving radioiodine therapy (RAI). The overall goal of this study is to find out if taking the study drug before RAI works better than receiving RAI alone (the usual standard of care treatment). 

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children, MRI/Imaging Studies

Lurbinectedin in Ewing Sarcoma
This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children

Lutathera in Somatostatin Neuroendocrine Tumors

This study involves taking a study drug called Lutathera.The overall goal of this study is to see if Lutathera is safe in adolescentsubjects with either a gastroenteropancreatic neuroendocrine tumor (GEP-NET),or a pheochromocytoma and/or paraganglioma (PPGL). This study will also look atthe levels of radioactivity after Lutathera administration.

Phase: Phase II

Actively recruiting: Yes

Category: Children

ON-TRK
The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment. This study will enroll participants with any tumors harboring the NTRK gene fusion including Soft Tissue Sarcomas, Central Nervous System, Melanoma, and Thyroid cancers.

Phase: N/A

Actively recruiting: Yes

Category: Adults, Children

Palbociclib, Irinotecan, and Temozolomide in Ewing Sarcoma
The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma and when given in combination with topotecan and cyclophosphamide in patients with neuroblastoma.

Phase: Phase II

Actively recruiting: Yes

Category: Adults, Children

Repotrectinib for ALK, ROS1, or NTRK1-3 Alterations
The purpose of this study is to test the safety and efficacy of the investigational drug called repotrectinib in children whose cancers have specific genetic changes (in the ALK, ROS1, or NTRK1-3 genes). This is the first study using this drug in children under 12 years of age. Repotrectinib is administered in capsule form or liquid suspension.  

Phase: Phase I, Phase II

Actively recruiting: Yes

Category: Adults, Children